Transarterial embolization of renal tumors improves surgical outcomes: A case series  by Reinhart, Henry A. et al.
T
o
H
a
S
b
S
a
A
R
A
A
K
R
S
E
1
i
n
i
h
i
e
i
w
s
i
c
T
M
h
2
cCASE  REPORT  –  OPEN  ACCESS
International Journal of Surgery Case Reports 15 (2015) 116–118
Contents lists available at ScienceDirect
International  Journal  of  Surgery  Case  Reports
j ourna l h om epage: www.caserepor ts .com
ransarterial  embolization  of  renal  tumors  improves  surgical
utcomes:  A  case  series
enry  A.  Reinharta,  Melhem  Ghalebb,  Brian  R.  Davisa,∗
Texas Tech University Health Sciences Center, Paul L. Foster School of Medicine, Department of Surgery, 4800 Alberta Avenue, El Paso, TX 79905, United
tates
Texas Tech University Health Sciences Center, Paul L. Foster School of Medicine, Department of Radiology, 5001 El Paso Drive, El Paso, TX 79905, United
tates
 r  t  i  c  l e  i  n  f  o
rticle history:
eceived 19 June 2015
ccepted 9 August 2015
vailable online 20 August 2015
eywords:
enal tumors
urgical outcomes
mbolization
a  b  s  t  r  a  c  t
INTRODUCTION:  Operative  treatment  of renal  tumors  can  be  associated  with  a high  rate  of perioperative
morbidity  related  to hemorrhage  and  injury  to adjacent  anatomical  structures.  This  morbidity  of  solid
organ  surgery  is  especially  prevalent  when  the lesion  involves  chronic  inﬂammation  or a desmoplastic
reaction  from  a rapidly  growing  tumor.  No  consensus  on  the  use  of  transarterial  embolization  has  been
fashioned  as  the  number  of  prospective  studies  is small.  This  study  proposes  to examine  the  beneﬁcial
effects  of selective  transarterial  embolization  of the  kidney  prior  to  surgical  resection.
PRESENTATION  OF  CASE:  A  retrospective  case  matched  review  was  performed  of  consecutive
nephroureterectomies  evaluating  outcomes  of patients  receiving  transarterial  embolization  versus  those
patients who  received  no embolization.  The  records  were  obtained  from  University  Medical  Center  of  El
Paso for  the time  period  of  05/2011–12/2014.  Data  examined  included  patient  demographics,  operative
blood  loss,  operative  time, transfusion  requirements,  and  pathology.  Previous  studies  have  shown  that
preoperative  embolization  of  renal  tumors  resulted  in  a decreased  need  for blood  transfusion.
CONCLUSION:  Our  review  showed  transarterial  embolization  had  a  decrease  in  blood  loss  and  required
no transfusions.  It  also  facilitated  a  larger  and  more  advanced  tumor  resection.  Our  series  of patients
tolerated  transarterial  embolization  well  and  had  good  surgical  outcomes.  Transarterial  embolization  of
kidneys prior  to  radical  nephroureterectomy  results  in  a safe  and  uncomplicated  operative  course  with
less perioperative  morbidity  when  compared  to  resection  alone.
.  Pub
he CC© 2015  The  Authors
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. Introduction
Transarterial embolization (TAE) is a technique that is increas-
ngly being used to augment surgical options for an increasing
umber of pathologies [1]. Renal cell cancer (RCC) is the 10th lead-
ng cause of cancer death in adult males in the United States. It
as also been increasing in incidence on a global scale [2,3]. The
ncrease is likely due to the use of CT imaging for other conditions
nhancing detection of incidentally found renal tumors. While the
ncidence of RCC is increasing, the amount of patients presenting
ith metastatic disease is alarmingly high at 20–30% [3].
Renal artery embolization was originally used to treat unre-
ectable renal cancers that were symptomatic but is now being
ncreasingly used to augment surgical resection [4,5]. Surgeons
Abbreviations: TAE, transarterial embolization; RCC, renal cell cancer; CT,
omputed tomography; ICD9 codes, International Classiﬁcation of Disease; TNM,
 = tumor, N = nodes, M = metastasis: classiﬁcation of malignant tumors.
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began to use renal embolization in the 1970s [6] since resection
of renal tumors can be associated with a high rate of perioper-
ative morbidity related to hemorrhage. No consensus on the use
of TAE has been fashioned as the number of prospective studies is
small. Due to the lack of consensus on preoperative TAE with resec-
tion versus surgery alone we  elected to investigate the differences
between the two modalities at our institution.
2. Presentation of case
A retrospective case matched control review was performed of
consecutive nephroureterectomy patients from the years of 2011
through 2014. The records for this study were obtained from the
University Medical Center of El Paso. Patients who received TAE
along with surgery were compared to those patients who  under-
went radical nephrectomy alone. ICD-9 codes were then used to
look through the patient database to ﬁnd the applicable subjects.
Codes included 55.39, 55.89, 59.0, 59.00, 59.02, 59.03, 59.09, 59.1,
59.11, 59.12, 59.19, 59.29, 59.91, 59.92, 00.25, 88.45, 88.51, and
38.86. Data examined included patient demographics, operative
blood loss, operative time, transfusion requirements, length of stay,
iates Ltd. This is an open access article under the CC BY-NC-ND license (http://
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Table  1
Stage TI of the non-embolization group.
Non-embolization group
Tumor size (cm) Stage Length (min) Blood loss (cc) PRBC Surgery
4 × 4 × 3 T1 117 25 0 Laparoscopic right nephrectomy
4  × 3 × 3 T1 138 50 0 Laparoscopic right nephrectomy
5  × 5 × 4 T1 83 1400 4 Left nephrectomy
6  × 6 × 5 T1 117 250 0 Laparoscopic right nephrectomy
Mean  5 × 4 × 4 114 431
Table 2
Higher stage tumors in the transarterial embolization group.
Transarterial embolization group
Tumor size (cm) Stage Length (min) Blood loss (cc) PRBC Surgery
8 × 6 × 5 T3 129 300 0 Laparoscopic rightnephrectomy
12  × 10 × 9 T2 261 400 0 Left nephrectomy
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t6  × 5 × 4 T1 128 
8  × 7 × 6 T2 122 
Mean  9 × 7 × 6 160 
umor pathology, stage, and type of surgery. Patients were all
reater than 18 years of age. There were a total of eight patients
ncluded in this study that met  the criteria. Exclusion criteria
ncluded patients undergoing surgery for nephrolithiasis, atrophic
idneys, and pyelonephritis.
Renal artery embolization was performed using coils (Cook or
nterlock) introduced selectively into the renal artery. Coils were
ntroduced until complete embolization was found on angiogra-
hy. The Seldinger technique was utilized with local anesthesia.
he time to surgery post embolization varied from several hours to
ne day. Nephrectomy was then performed utilizing a laparoscopic
echnique or open surgery.
Four patients underwent radical nephroureterectomy with pre-
perative TAE for clear cell carcinoma. One patient had laparoscopic
hand assisted) surgery; the remaining patients received open
urgery. Operative blood loss averaged 250 cc and average oper-
tive time was 160 min. Three underwent TAE of the affected
idney the day of surgery while one underwent embolization
he day before surgery. Average dimensions of the tumor were
 cm × 7 cm × 6 cm.  One patient was TNM stage T1, two were T2,
nd the last was T3. None required blood transfusion. Three had
n uneventful postoperative course and were discharged on day
hree of hospitalization. One developed a pulmonary embolism and
as discharged on day thirteen. The average age was 57.5 years
ld (range 49–61). There were no reports of the post-embolization
yndrome of fever or pain since the embolizations were performed
ithin 24 h of nephrectomy.
Case-matched control methods identiﬁed four patients under-
oing nephroureterectomy for renal clear cell cancer without
ngioembolization. Three of the four patients had laparoscopic
ephrectomy for low stage tumors. Surgical blood loss had a mean
f 431 cc. The duration of surgery averaged 114 min. Average tumor
ize of this group was 5 cm × 4 cm × 4 cm.  Average length of stay for
his group was 3.25 days. The average age of this group was 49.75
range 32–57). All tumors were stage T1 (Table 1).
In comparison between the two groups, TAE allowed higher
tage tumors of greater average size to be removed with decreased
lood loss and comparable outcomes. There was no statistical dif-
erence between the two groups for operative blood loss or length
f stay (Table 2).. Conclusion
Transarterial embolization (TAE) is recognized as a technique
hat facilitates neprhectomy in selected patients. There have200 0 Right nephrectomy
100 0 Right nephrectomy
250
been demonstrated reductions in transfusion requirements, intra-
operative blood loss and duration of surgery in patients with
tumors of either large size or advanced stage [7]. Beneﬁts include
decreased tumor vascularity which allows early ligation of the renal
vein. TAE is especially useful in cases where the tumor involves the
renal hilum [8].
While the small sample size of our study limited the power of
our ﬁndings we did see similarities to other studies. Zielinski et al.
demonstrated an increase in ﬁve and ten year survival with TAE
when compared to surgery alone. This was a non-randomized study
at a single institution and the difference only applied to T2 and T3
tumors [9]. A more recent study by May  et al. found no difference
in survival between patients treated with surgery and TAE com-
pared to surgery alone. These ﬁndings may  be inaccurate as follow
up was  longer for the TAE group. This same study also found no
signiﬁcant difference in complications although there was a sig-
niﬁcant increase in the transfusion requirement for the non-TAE
group (p < 0.01) [10].
Surgeons recommend TAE prior to surgery as it aids in dissection
due to edema of the tissue planes. There are also some surgeons
who hypothesize that increased survival with TAE is due to the
immunomodulatory effect of the embolization. Post embolization
tumor necrosis upregulates a lymphoproliferative state and with a
speciﬁc tumor response of natural killer cells [11,12]. TAE is usually
well tolerated with a small number of patients complaining of post
infarction syndrome characterized by nausea, pain, and fever [13].
Complications associated with TAE have been reported by Lammer
et al. to include erroneus infarction of bowel, contralateral kidney
and spine with a mortality of 3.3% and serious morbidity of 9.9% in
a series of 121 procedures [14].
Studies have demonstrated that preoperative TAE has been
associated with decreased blood loss which is consistent with ﬁnd-
ings from our institution [7]. TAE facilitates resection of a larger
and more advanced stage tumor with comparable blood loss to
nephrectomy alone. Shortcomings with our study are associated
with the low power, the case-matched format and the technique
of embolization with coils. Coils have been demonstrated to be less
effective in embolization as the current preferred technique uses
n-butyl cyanoacrylate glue which allows rapid and deﬁnitive dis-
tal occlusion of a voluminous vascular bed and causes necrosis in
perivascular tissue [15]. While TAE prior to operative intervention
has been shown to decrease blood loss for advanced stage tumors,
prospective randomized trials are needed to demonstrate a survival
beneﬁt from renal artery embolization combined with surgery.
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